Last reviewed · How we verify
Pancreatic Clamp
Pancreatic Clamp is a Small molecule drug developed by Albert Einstein College of Medicine. It is currently in Phase 2 development. Also known as: Clamp.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Pancreatic Clamp |
|---|---|
| Also known as | Clamp |
| Sponsor | Albert Einstein College of Medicine |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Sleep Loss and Circadian Misalignment - Mechanisms of Insulin Resistance (PHASE4)
- The Role of Glucagon in Glucose Metabolism in Humans With and Without Bariatric Surgery (PHASE1)
- The Effects of Glucagon on Hepatic Metabolism (PHASE1, PHASE2)
- Comparison of the Pharmacokinetics (PK) and Pharmacodynamics (PD) Biosimilarity of Proposed Biosimilar Rapid-Acting Insulin Aspart (I004) and NovoLog After Single-Dose Subcutaneous Administration to Healthy Volunteers (PHASE2, PHASE3)
- Reprometabolic Syndrome Mediates Subfertility in Obesity (NA)
- Human Models of Selective Insulin Resistance: Pancreatic Clamp (PHASE1)
- Measuring Amino Acid and Glucose Metabolism in Healthy Volunteers and NAFLD Patients Using Total-body PET (NA)
- A Study of LY3938577 in Healthy Participants and Participants With Type 1 Diabetes Mellitus (T1DM) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pancreatic Clamp CI brief — competitive landscape report
- Pancreatic Clamp updates RSS · CI watch RSS
- Albert Einstein College of Medicine portfolio CI
Frequently asked questions about Pancreatic Clamp
What is Pancreatic Clamp?
Who makes Pancreatic Clamp?
Is Pancreatic Clamp also known as anything else?
What development phase is Pancreatic Clamp in?
Related
- Manufacturer: Albert Einstein College of Medicine — full pipeline
- Also known as: Clamp
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing